Head-to-head evidence
bevacizumab-awwb vs HLX04
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
bevacizumab-awwb · MVASI
Marketed by Amgen
NCT01966003 · Phase 3 · completed
This randomized, quadruple-blind, active-controlled Phase 3 trial in 642 patients with advanced non-small cell lung cancer compared the biosimilar bevacizumab-awwb with reference bevacizumab, both added to chemotherapy. Objective response rates were closely matched (39.0% vs 41.7%), and the prespecified statistical test showed the two products were clinically equivalent.
HLX04
Developed by Shanghai Henlius Biotech
NCT03952403 · Phase 3 · status unknown
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The first listed primary outcome for this study is Part 1 safety and tolerability; the survival figures shown here are the Part 2 primary endpoint (progression-free survival) and the overall-survival secondary endpoint from the final analysis.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bevacizumab-awwb's landscape · HLX04's landscape